This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment Resistant Bipolar Depression

This study has been terminated.
(Lundbeck withdrew committment - expiring patents and prolonged inactivity)
Information provided by (Responsible Party):
Dr. Roumen Milev, Queen's University Identifier:
First received: January 3, 2006
Last updated: December 14, 2015
Last verified: December 2015
January 3, 2006
December 14, 2015
October 2006
January 2010   (Final data collection date for primary outcome measure)
To evaluate the response rates when Escitalopram vs. placeboes added to the current mood stabilizer or antipsychotic medication [ Time Frame: 6 weeks ]
To evaluate improvement
Complete list of historical versions of study NCT00272025 on Archive Site
To evaluate efficacy, safety and tolerability of added Escitalopram, to a mood stabilizer or atypical antipsychotic. [ Time Frame: 6 weeks ]
Not Provided
Not Provided
Not Provided
Treatment Resistant Bipolar Depression
Six Week Double Blind, Randomized Trial of Escitalopram Add On for Treatment Resistant Bipolar Depression
To determine if adding Escitalopram to current mood stabilizer (MS) or atypical antipsychotic (AA) will improve in rates similar to or better than adding a placebo (inactive pill)in resistant bipolar patients.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Bipolar Depression
  • Drug: Escitalopram
    10mg to 20mg tablet daily for 6 weeks
    Other Name: Cipralex
  • Drug: placebo
  • Active Comparator: 1
    There is a 50% chance of being randomized to Escitalopram in addition to current atypical antipsychotic (minimum dose risperidone 3mg, olanzapine 10mg or seroquel 400mg) or mood stabilizer (lithium, epival or lamotrigine)
    Intervention: Drug: Escitalopram
  • Placebo Comparator: 2
    to be filled in
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2010
January 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18 or older
  • Diagnosis of Bipolar Disorder and currently be in depressive state, and not responded to mood stabilizer or atypical antipsychotic alone or combined with an antidepressant medication.

Exclusion Criteria:

  • Pregnant or breastfeeding
  • History of seizure disorder or other unstable medical condition
  • Received Electroconvulsive Therapy or Transcranial Magnetic Stimulation in the last three months
  • Experienced hallucinations or delusions
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Dr. Roumen Milev, Queen's University
Queen's University
Not Provided
Principal Investigator: Roumen V. Milev, MD Queen's University
Queen's University
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP